Clinical trial methods to discover and validate predictive markers for treatment response in cancer
Clinical trial methods to discover and validate predictive markers for treatment response in cancer
复制标题
DOI：
10.1016/s1387-2656(03)09005-7
复制
发表时间：
2003-01-01
期刊：
影响因子：
--
通讯作者：
Paik, S
中科院分区：
文献类型：
--
作者：
Paik, S
虽然癌症的术后化疗似乎已经达到了细胞减少的极限，但这可能是由于化疗药物的非选择性施用而不是达到细胞减少的真正极限。肿瘤细胞的分子特征可能决定肿瘤对化疗的反应，因此基于预测的选择性化疗将最终提供治愈乳腺癌的方法。本文讨论了旨在揭示预测标志物的临床试验设计策略。
Although postoperative chemotherapy in the treatment of cancer appears to have reached the limit of cytoreduction, this may be due to chemotherapeutic agents that are administered nonselectively rather than attainment of the true limit of cytoreduction. Molecular profiles of tumor cells may determine tumor response to chemotherapy, and therefore the selective use of chemotherapy based on prediction will ultimately provide a cure for breast cancer. In this paper, design strategies for clinical trials aimed at disclosing predictive markers are discussed.